Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
How would you manage a patient with erosive seronegative rheumatoid arthritis with IgG and IgM deficiency?
Related Questions
Can you use leflunomide and rituximab in a patient with both multiple sclerosis and rheumatoid arthritis?
Do you feel comfortable using Jak inhibitors in patients with a strong family history of CAD, but no other risk factors?
How do you approach treatment of early onset RA with minimal peripheral disease and aggressive cervical atlantoaxial involvement?
Does the presence of bronchiectasis change your approach to a patient with otherwise well-controlled patient with RA?
How do you approach treatment selection in patients with rheumatoid arthritis and severe COPD?
Do you consider new onset autoimmune disease (e.g. seronegative rheumatoid arthritis) a few months after completing immunotherapy for cancer to be an immune-related adverse effect to the immunotherapy?
What is your approach for cancer screening for elderly onset RA?
How would you approach a patient with seronegative RA and ILD?
Does the presence of calcified granulomas on chest imaging influence your choice of biologic for treatment of psoriatic arthritis (or rheumatoid arthritis)?
What is your approach to differentiating and managing DMARD-induced nodulosis (induced by methotrexate or leflunomide for example) from "de novo" RA nodules in seropositive RA patients?
